Priorix Tetra: Uses, Dosage & Side Effects
A combined live attenuated vaccine protecting children against measles, mumps, rubella and varicella (chickenpox) in a single injection
Priorix Tetra is a combined live attenuated vaccine used in children from 11 months to 12 years of age to provide active immunization against four vaccine-preventable diseases: measles, mumps, rubella, and varicella (chickenpox). It is given as a single 0.5 mL subcutaneous or intramuscular injection after reconstitution of the lyophilized powder with the supplied solvent. Priorix Tetra offers the convenience of four vaccines in one visit, reducing the total number of injections children need in the routine immunization schedule. Clinical trials have demonstrated high seroconversion rates exceeding 96% for all four viral components after a single dose, with two-dose schedules providing robust, long-lasting protection. The vaccine has an extensive safety record, with most adverse reactions being mild injection-site reactions or transient fever.
Quick Facts: Priorix Tetra
Key Takeaways
- Priorix Tetra is a combined live attenuated vaccine that protects against four diseases in one injection: measles, mumps, rubella, and varicella (chickenpox), simplifying the childhood immunization schedule.
- It is authorized for children aged 11 months through 12 years, typically given as two doses according to national immunization schedules, with the first dose around 12–15 months and the second before school entry.
- A single dose produces protective antibody responses in approximately 96–99% of vaccinated children against all four viruses, and two doses provide durable, long-lasting immunity.
- The most common side effects are mild injection-site reactions, fever, and sometimes a transient rash. Febrile seizures are a known, rare risk particularly after the first dose of combined MMRV vaccines.
- Priorix Tetra must not be given during pregnancy or to individuals with severe immunodeficiency, and a 4-week interval is required when given with other live vaccines that are not administered on the same day.
What Is Priorix Tetra and What Is It Used For?
Priorix Tetra is a combined measles, mumps, rubella, and varicella (MMRV) vaccine manufactured by GlaxoSmithKline (GSK) Biologicals. It is designed to provide active immunization of children from 11 months through 12 years of age against four serious and highly contagious viral infections that were historically major causes of morbidity and mortality in children worldwide. By combining four live attenuated viruses into a single injection, Priorix Tetra simplifies the childhood vaccination schedule, reduces the number of injections children need, and improves vaccine coverage in routine immunization programs.
Each of the four viral components has been carefully selected and attenuated (weakened) in the laboratory so that the resulting vaccine strains can replicate enough in the vaccinated child to trigger a robust immune response, but not enough to cause the full clinical disease. After vaccination, the immune system recognizes the viral antigens, produces specific antibodies (humoral immunity), and develops memory T cells (cellular immunity) that provide protection against future exposure to the wild-type viruses. This protective immunity typically lasts for many years, and in many cases throughout life.
The four diseases that Priorix Tetra protects against are:
- Measles (morbilli): One of the most contagious human diseases known, caused by the measles virus. Measles can cause high fever, characteristic rash, cough, conjunctivitis, and serious complications including pneumonia, encephalitis (brain inflammation), and subacute sclerosing panencephalitis (SSPE), a rare but fatal degenerative brain disease that can develop years after infection.
- Mumps (parotitis epidemica): A viral infection characterized by swelling of the parotid (salivary) glands, fever, and general malaise. Complications can include meningitis, encephalitis, orchitis (testicular inflammation) in adolescent and adult males, oophoritis, pancreatitis, and permanent hearing loss.
- Rubella (German measles): Generally a mild illness in children with low-grade fever and rash, but devastating if contracted during pregnancy. Congenital rubella syndrome (CRS) can cause severe birth defects including congenital cataracts, deafness, heart defects, and intellectual disability. Eliminating rubella circulation through widespread childhood vaccination is essential to prevent CRS.
- Varicella (chickenpox): Caused by the varicella-zoster virus (VZV), varicella typically presents with a widespread itchy vesicular rash, fever, and general malaise. Complications include bacterial superinfection, pneumonia, neurological complications such as cerebellar ataxia, and rarely, severe disseminated disease. The same virus can later reactivate as herpes zoster (shingles).
Before widespread vaccination, these four diseases caused substantial global morbidity. Measles alone was responsible for millions of deaths each year in children worldwide in the pre-vaccine era, and measles remains a leading cause of vaccine-preventable childhood death in regions with low immunization coverage. According to the World Health Organization (WHO), measles vaccination prevented an estimated 56 million deaths between 2000 and 2021, yet measles continues to cause outbreaks when vaccination coverage falls below the herd immunity threshold of approximately 95%.
Priorix Tetra is indicated for the active immunization of children from the age of 11 months to 12 years (the exact lower age limit may vary by country and may be extended to 9 months in specific epidemiological situations, such as during outbreaks, at the discretion of the healthcare provider). The vaccine is typically administered as part of national routine immunization programs. Most countries in Europe, and many globally, include measles-mumps-rubella (MMR) or MMRV vaccination in their routine childhood schedules, with varying recommendations on whether to use MMR plus varicella as separate injections or combined MMRV such as Priorix Tetra.
The vaccine strains in Priorix Tetra are the Schwarz strain of measles, the RIT 4385 strain of mumps (derived from the well-characterized Jeryl Lynn strain), the Wistar RA 27/3 strain of rubella, and the Oka strain of varicella-zoster virus. These strains have been used in vaccines for decades and have extensive safety and efficacy data supporting their use. The measles, mumps, and rubella components are propagated in chick embryo fibroblast cell culture (measles and mumps) or human diploid cells (MRC-5) for rubella, while the varicella component is propagated in human diploid MRC-5 cells.
Widespread childhood MMRV vaccination is the cornerstone of measles and rubella elimination strategies globally. The WHO, UNICEF, and national public health authorities consistently emphasize that achieving and maintaining two-dose MMR or MMRV coverage of at least 95% in every community is essential to prevent outbreaks and ultimately eliminate these diseases. Delaying or skipping vaccination not only places the individual child at risk but also contributes to community-wide vulnerability.
What Should You Know Before Taking Priorix Tetra?
Contraindications
Priorix Tetra must not be administered under the following circumstances. The absolute contraindications to vaccination are:
- Hypersensitivity: Known severe allergic reaction (e.g., anaphylaxis) to a previous dose of Priorix Tetra, any MMR or MMRV vaccine, or any ingredient listed in the vaccine, including trace amounts of neomycin, which may be present as a residue from the manufacturing process.
- Severe immunodeficiency: Priorix Tetra is a live vaccine and must not be given to individuals with severe primary or acquired immunodeficiency, including patients with severe combined immunodeficiency (SCID), DiGeorge syndrome with complete T-cell absence, untreated HIV infection with severe immunosuppression, ongoing high-dose immunosuppressive therapy, or hematologic malignancies not in remission. In these individuals, the attenuated vaccine viruses may replicate uncontrollably and cause severe or fatal vaccine-strain disease.
- Pregnancy: Priorix Tetra must not be given to pregnant women. As a live vaccine, there is a theoretical risk of fetal harm, particularly from the rubella and varicella components. Pregnancy should be avoided for at least one month after vaccination.
- Active untreated tuberculosis: Vaccination should be deferred until tuberculosis is under treatment.
Warnings and Precautions
Minor infections without fever (such as a mild cold) are not a reason to postpone vaccination. However, in the presence of moderate or severe acute febrile illness, vaccination should be deferred until the child has recovered. This is to avoid confusing vaccine reactions with symptoms of the underlying illness.
Before administering Priorix Tetra, healthcare providers should carefully review the child's medical history, discuss any concerns with parents or caregivers, and consider the following precautions:
- History of severe allergic reactions: Priorix Tetra contains trace amounts of neomycin (an antibiotic used in manufacturing). A history of contact dermatitis from neomycin is not a contraindication, but a history of anaphylactic reaction to neomycin is. As with all vaccines, appropriate medical treatment (including adrenaline) should be readily available in case of a rare anaphylactic reaction following administration.
- Egg allergy: The measles and mumps components of Priorix Tetra are produced in chick embryo cell culture and may contain trace amounts of egg protein. Current guidance from WHO, EMA, CDC, and other authorities is that children with egg allergy, including severe allergy, can generally receive MMR and MMRV vaccines safely in routine settings. Severe allergic reactions to MMRV vaccines are more often attributed to other vaccine components rather than egg.
- Thrombocytopenia: Transient mild thrombocytopenia (low platelet count) has been reported within 6 weeks following primary vaccination with MMR-containing vaccines, typically resolving spontaneously. Children with a history of thrombocytopenic purpura after a previous dose may be at increased risk and should be evaluated individually.
- History of febrile seizures or family history of seizures: Combined MMRV vaccines have been associated with a small increased risk of febrile seizures 5–12 days after the first dose, compared with separate administration of MMR and varicella vaccines. This risk is small in absolute terms (approximately one additional febrile seizure per 2,300–2,600 doses of MMRV compared to separate MMR + varicella). National guidance varies on which combination to use for the first dose.
- Recent blood products or immunoglobulin: Antibodies in immunoglobulin preparations or blood products can interfere with the immune response to live viral vaccines. An appropriate waiting interval (typically 3 to 11 months, depending on the product and dose) should be observed before administering Priorix Tetra.
- Household contacts who are immunocompromised or pregnant: Vaccine viruses are generally not transmitted to contacts, although very rare transmission of vaccine-strain varicella has been reported. Children with household contacts who are immunosuppressed or pregnant can still be vaccinated; standard hygiene practices should be followed.
Children and Adolescents
Priorix Tetra is specifically indicated for children aged 11 months to 12 years. The immune response and safety profile in this age group are well-characterized from extensive clinical trials and post-marketing experience. For children younger than 9 months, maternal antibodies may still interfere with the vaccine response, and immunization is generally deferred. For individuals older than 12 years requiring MMR and varicella protection, separate MMR and varicella vaccines are typically used, as the combined MMRV formulation is not licensed in older populations.
Pregnancy and Breastfeeding
Priorix Tetra must not be given during pregnancy. As with other live rubella-containing vaccines, pregnancy should be avoided for at least one month after vaccination. This precaution is based on theoretical concerns about fetal infection with attenuated virus strains. However, inadvertent vaccination during early pregnancy has been extensively monitored through pregnancy registries, and no increased risk of congenital rubella syndrome or other congenital malformations has been demonstrated. Therefore, inadvertent vaccination is not considered an indication for termination of pregnancy, but such cases should be reported to pregnancy registries and discussed with an obstetric specialist.
Priorix Tetra can generally be given to breastfeeding mothers when indicated, although this is not a typical situation because the vaccine is intended for children. Vaccine-strain rubella virus has been detected in breast milk of vaccinated mothers in rare cases, but transmission to the infant with clinically significant disease has not been demonstrated.
Driving and Operating Machinery
Because Priorix Tetra is administered to children, effects on driving and operating machinery are not applicable. In older recipients (if vaccinated), the vaccine is not expected to impair these abilities, although fatigue or mild fever may be present for 1–2 days.
Important Information About Ingredients
Priorix Tetra contains amino acids, lactose, mannitol, sorbitol, medium 199 components, sucrose, and trace amounts of neomycin. It contains essentially no gluten and no preservatives such as thiomersal. Individuals with rare hereditary fructose intolerance should not receive Priorix Tetra because it contains sorbitol. The total sorbitol content per dose is small but relevant for individuals with this rare condition.
How Does Priorix Tetra Interact with Other Drugs?
Understanding how Priorix Tetra interacts with other medications, vaccines, and biological products is essential to ensuring both safety and a robust immune response. Because Priorix Tetra is a live attenuated vaccine containing four different viral strains, the most clinically important interactions are immunological rather than pharmacokinetic. The general principles below reflect international guidance from WHO, ECDC, CDC ACIP, and national immunization technical advisory groups.
Most interactions involve the potential for other agents to either suppress the immune response to the vaccine (reducing its effectiveness) or to increase the risk of certain adverse events. Unlike small-molecule drugs, vaccines do not interact through cytochrome P450 enzyme pathways, so standard drug-drug interaction screening does not identify vaccine-relevant interactions; instead, specific immunological considerations apply.
Major Interactions
| Interacting Agent | Effect | Management |
|---|---|---|
| Immunoglobulin preparations / blood products | Passive antibodies can neutralize vaccine viruses and reduce immunogenicity | Delay Priorix Tetra by 3–11 months after immunoglobulin, depending on dose and product |
| Immunosuppressive therapy (high-dose corticosteroids, chemotherapy, biologics, radiation) | Suppressed immune response and potential uncontrolled replication of vaccine strains | Defer vaccination during immunosuppression; timing of post-treatment vaccination determined by specialist |
| Other live attenuated vaccines (not given on same day) | Theoretical reduced immunogenicity due to viral interference | Separate by at least 4 weeks |
| Salicylates (high-dose aspirin) | Theoretical risk of Reye syndrome in children after varicella | Avoid salicylates for 6 weeks after Priorix Tetra in children and adolescents |
| Antiviral medications active against herpesviruses (acyclovir, valacyclovir, famciclovir) | May reduce effectiveness of the varicella component | Avoid these antivirals for at least 14 days before and 14 days after vaccination when possible |
| Tuberculin skin test (TST) / IGRA | MMR-containing vaccines may suppress TST reactivity for up to 4–6 weeks, causing false-negative results | Perform TST on the same day as vaccination or delay by at least 4 weeks |
Minor Interactions and Co-Administration
Priorix Tetra can be safely given at the same visit as a wide range of other routine childhood vaccines without reducing the immune response to either. This is a major practical benefit, as it allows healthcare providers to bring children fully up to date with several vaccines at a single visit and minimizes the number of clinic trips required for routine immunization.
Vaccines that are commonly co-administered with Priorix Tetra include:
- DTP-containing vaccines: Diphtheria-tetanus-acellular pertussis vaccines, either alone or in combination with Haemophilus influenzae type b (Hib), inactivated poliovirus (IPV), and hepatitis B.
- Pneumococcal conjugate vaccines (PCV10, PCV13, PCV15, PCV20): Commonly co-administered with MMRV in routine schedules at 12–15 months.
- Meningococcal conjugate vaccines (MenACWY, MenB): No clinically significant interaction.
- Hepatitis A vaccine: Can be co-administered without issue.
- Rotavirus vaccines (live oral): Generally given in earlier infancy, but no clinically significant interaction if ages overlap.
- Influenza vaccine (inactivated): Can be given at the same visit as Priorix Tetra.
- COVID-19 vaccines: Can be co-administered with Priorix Tetra in pediatric schedules where indicated, following national guidance.
When co-administering Priorix Tetra with another vaccine, different injection sites should be used. If using the same limb (e.g., both in the thigh of a young child), a separation of at least 2.5 cm between injection sites is recommended.
Before your child receives Priorix Tetra, inform the healthcare provider about any current or recent medications (including over-the-counter products and herbal supplements), any ongoing medical conditions, any recent vaccinations (especially live vaccines), any recent blood products or immunoglobulins, and any history of severe allergic reactions. This information helps ensure that the vaccine is administered safely and effectively.
What Is the Correct Dosage of Priorix Tetra?
Priorix Tetra should only be administered by a qualified healthcare professional trained in vaccine administration and emergency management of rare anaphylactic reactions. The vaccine is supplied as a lyophilized (freeze-dried) powder together with a solvent (sterile water for injections) in a pre-filled syringe. The powder must be reconstituted with the entire contents of the solvent immediately before administration, and the reconstituted vaccine must be used within one hour and stored refrigerated during that time. The final reconstituted dose volume is 0.5 mL.
Reconstitution is performed by first injecting the solvent into the vial containing the lyophilized powder, swirling gently until fully dissolved, and then withdrawing the full dose volume into the syringe. The reconstituted vaccine should be clear and colorless to slightly yellow. It should not be used if it appears cloudy, discolored, or contains visible particles after adequate mixing.
Recommended Doses
| Population | Dose | Number of Doses | Typical Timing |
|---|---|---|---|
| Children 11 months to 12 years | 0.5 mL | 2 doses | First: 11–15 months; Second: before school entry |
| Catch-up vaccination (previously unvaccinated children under 13) | 0.5 mL | 2 doses | Minimum 4-week interval between doses |
| Outbreak / travel (from 9 months) | 0.5 mL | Early dose + 2 routine doses | Early dose at 9–11 months; routine two-dose series still given |
If a dose is given before 11 months of age (for example during a measles outbreak or before international travel), this early dose is considered a supplementary dose and does not count toward the routine two-dose schedule. The routine two doses should still be administered at the recommended ages to ensure long-term immunity.
Route and Site of Administration
Priorix Tetra is administered by subcutaneous injection (preferred in young children) or intramuscular injection. The recommended injection sites are:
- Anterolateral thigh: Preferred in infants and toddlers under approximately 15 months of age, due to greater muscle mass in this region.
- Deltoid muscle (upper arm): Preferred in older children whose deltoid is sufficiently developed, typically from 15 months of age onwards.
The vaccine must not be administered intravascularly or intradermally under any circumstances. After injection, the child should be observed for at least 15 minutes for any immediate adverse reactions, including rare anaphylactic reactions.
Children Under 11 Months
Priorix Tetra is not routinely recommended for infants under 11 months of age because of interference from maternal antibodies, which can reduce the immune response. In specific situations such as measles outbreaks, humanitarian emergencies, or international travel to high-risk areas, early vaccination at 9–11 months may be recommended by public health authorities. In these cases, the early dose does not replace the routine two-dose schedule at the recommended ages.
Adolescents and Adults Over 12 Years
Priorix Tetra is not licensed for use in adolescents over 12 years or in adults. For older individuals requiring protection against measles, mumps, rubella, or varicella, separate MMR and varicella vaccines are typically used, administered on the same day or at least 4 weeks apart. The two-dose schedule remains standard for both vaccines.
Renal and Hepatic Impairment
No specific studies have been performed in children with renal or hepatic impairment. As a live attenuated vaccine, Priorix Tetra is not metabolized through the kidneys or liver, and dose adjustments are not expected to be needed. However, vaccination in children with severe underlying conditions should be discussed with the treating specialist, taking into account the overall immune status.
Missed Dose or Delayed Schedule
If the scheduled second dose of Priorix Tetra is delayed, it should be given as soon as possible. The schedule does not need to be restarted; doses already received still count. The minimum interval between the first and second doses is 4 weeks; there is no maximum interval, so a delay does not require re-starting the series. Contact your healthcare provider to reschedule as soon as you realize a dose has been missed.
Overdose
Administration of more than the recommended dose is extremely unlikely given that each pre-filled syringe contains a single 0.5 mL dose. However, if inadvertent administration of a higher dose occurs, the child should be monitored for adverse reactions. No specific antidote exists, and management is supportive. Cases of inadvertent double-dose administration in the literature have not shown increased rates of serious adverse events.
Preparation and Administration by Healthcare Professionals
Healthcare professionals administering Priorix Tetra should follow these steps:
- Preparation: Remove the vial of lyophilized vaccine and the pre-filled syringe of solvent from the refrigerator. Allow to reach room temperature briefly before reconstitution.
- Reconstitution: Attach the needle to the syringe. Inject the entire contents of the solvent into the vial of powder. Swirl gently (do not shake vigorously) until the powder is fully dissolved.
- Inspection: Inspect the reconstituted vaccine visually. It should be clear and colorless to slightly yellow. Discard if cloudy, discolored, or particulate matter is visible.
- Withdrawal: Withdraw the full reconstituted dose (0.5 mL) into the syringe. Change the needle to a fresh sterile needle appropriate for the injection route and site.
- Injection: After cleaning the injection site with alcohol and allowing to dry, administer subcutaneously (preferred) or intramuscularly. Do not inject intravascularly.
- Disposal: Dispose of the used syringe, needle, and vial in an approved sharps container according to local biohazard waste regulations.
The reconstituted vaccine must be used within 1 hour; unused reconstituted vaccine should be discarded. Documentation of the vaccine lot number, administration date, site, and healthcare provider should be recorded in the child's immunization record according to local practice.
What Are the Side Effects of Priorix Tetra?
Like all vaccines, Priorix Tetra can cause side effects, although most vaccinated children experience no or only mild reactions. The safety profile has been established through extensive clinical trials involving thousands of children and more than two decades of post-marketing surveillance in dozens of countries. The side effects observed are consistent with those expected from live attenuated MMR and varicella vaccines and reflect the immune response to the vaccine components.
Some reactions (such as fever and rash) typically occur 5–12 days after vaccination, coinciding with the peak replication of the vaccine viruses. These delayed reactions are generally transient and mild, but should be distinguished from the wild-type infections the vaccine is designed to prevent. The frequencies listed below reflect the rates observed in clinical trials and post-marketing experience.
Very Common
May affect more than 1 in 10 people
- Pain and redness at the injection site
- Fever (axillary temperature ≥ 37.5 °C, rectal ≥ 38 °C)
- Irritability
Common
May affect up to 1 in 10 people
- Injection site swelling
- High fever (axillary > 39 °C, rectal > 39.5 °C)
- Upper respiratory tract infection symptoms
- Rash (including measles-like and varicella-like rash)
- Loss of appetite
- Diarrhea or vomiting
- Sleepiness, restlessness, insomnia
- Mild conjunctivitis
Uncommon
May affect up to 1 in 100 people
- Middle ear infection (otitis media)
- Lymphadenopathy (swollen lymph nodes)
- Cough or bronchitis
- Parotid (salivary) gland enlargement
- Febrile seizures (particularly 5–12 days after first MMRV dose)
Rare
May affect up to 1 in 1,000 people
- Transient thrombocytopenia (low platelet count)
- Allergic reactions including urticaria (hives), angioedema
- Purpura (skin bruising)
- Kawasaki-like symptoms (very rare association)
Very Rare / Not Known
Frequency cannot be estimated from available data
- Anaphylaxis (severe allergic reaction)
- Encephalitis, meningitis, encephalopathy (extremely rare causal association; background rate difficult to separate)
- Acute disseminated encephalomyelitis (ADEM)
- Guillain-Barré syndrome
- Transverse myelitis, peripheral neuritis
- Erythema multiforme
- Arthralgia, arthritis (more common in post-pubertal females after rubella vaccination)
Fever following Priorix Tetra typically occurs 5–12 days after vaccination and is usually short-lived, lasting 1–2 days. In clinical studies, fever of any grade was reported in approximately 30–40% of children after the first dose and slightly less after the second dose. Antipyretic medication such as paracetamol (acetaminophen) can be used to manage fever if needed, although prophylactic antipyretics at the time of vaccination are not routinely recommended because they may slightly reduce the immune response in some settings.
A measles-like rash can appear 5–12 days after vaccination in a small percentage of children and reflects the expected replication of the attenuated measles vaccine virus. This post-vaccination rash is distinguishable from wild-type measles: it is typically milder, shorter in duration, and not associated with the full constellation of measles symptoms (cough, coryza, conjunctivitis, and Koplik spots). A small number of vesicles resembling varicella can also appear, reflecting the replication of the vaccine-strain varicella-zoster virus.
Febrile seizures are a recognized risk of live viral vaccines and are slightly more common with combined MMRV vaccines (such as Priorix Tetra) than with separate MMR and varicella vaccines given on the same day. The excess risk is approximately one additional febrile seizure per 2,300–2,600 doses of MMRV in the 5–12 day post-vaccination window, and this risk primarily affects the first dose in children under 2 years of age. Febrile seizures, while frightening for parents, are generally brief, self-limited, and not associated with long-term neurological consequences. National immunization guidelines vary in whether they recommend MMRV or separate vaccines for the first dose; parents should discuss with their healthcare provider.
Serious allergic reactions, including anaphylaxis, are very rare following Priorix Tetra (estimated at fewer than 1 per million doses). Healthcare providers administering the vaccine are trained to recognize and treat such reactions promptly, and all clinics administering vaccines have adrenaline and other emergency medications available. A history of severe allergic reaction to a prior dose of MMR or MMRV is a contraindication to further doses.
Contact your healthcare provider or seek emergency care if your child experiences: difficulty breathing, swelling of the face or throat, a widespread severe rash, a seizure, prolonged high fever unresponsive to antipyretics, unusual bruising or bleeding, or severe lethargy or reduced responsiveness. Routine mild fever, irritability, or injection-site reactions can usually be managed at home with rest, fluids, and paracetamol if needed.
How Should You Store Priorix Tetra?
Proper storage of Priorix Tetra is essential to ensure that the vaccine retains its potency and safety at the time of administration. Like other live attenuated vaccines, Priorix Tetra is sensitive to temperature excursions, particularly heat, which can rapidly inactivate the viral components and render the vaccine ineffective. Robust cold-chain management from manufacturer to point-of-care is a critical public health concern.
Follow these storage requirements carefully:
- Refrigerated storage (powder vial): Store the lyophilized powder in a refrigerator at 2–8 °C (36–46 °F). Keep the vials in the original outer carton to protect from light.
- Solvent storage: The solvent (sterile water for injections in a pre-filled syringe) can be stored in the refrigerator (2–8 °C) or at ambient temperatures up to 25 °C, separately from the powder if necessary. Refer to the specific labeling for your batch.
- Do not freeze: Freezing the powder or the reconstituted vaccine can damage the structure of the viral particles and inactivate the vaccine. If the vaccine has been accidentally frozen, do not use it.
- Protect from light: The viral components are sensitive to UV light. Always store in the original carton and minimize light exposure.
- Transport: During transport between storage and administration sites, maintain 2–8 °C using validated cold-chain equipment. Monitor temperature throughout transit.
- Reconstituted vaccine: Once reconstituted with the solvent, the vaccine must be used within 1 hour. If not immediately used, the reconstituted product can be kept refrigerated at 2–8 °C during this 1-hour window; any vaccine not used within 1 hour must be discarded.
- Expiration date: Do not use Priorix Tetra after the expiration date printed on the carton and vial. The expiration date refers to the last day of the month.
- Inspection before reconstitution: Before reconstitution, inspect the powder for any abnormalities. After reconstitution, inspect the vaccine solution — it should be clear and colorless to slightly yellow. Do not use if cloudy, discolored, or if particles are present after gentle mixing.
- Keep out of reach of children: As with all medicines, store Priorix Tetra out of the reach and sight of children.
- Proper disposal: Used syringes, vials, and needles must be placed in an approved sharps container for medical waste disposal according to local biohazard regulations. Do not discard in household waste.
Vaccination clinics and pharmacies maintaining Priorix Tetra should use calibrated refrigerators with continuous temperature monitoring and alarms for out-of-range conditions. Any temperature excursion outside 2–8 °C should be documented, and the affected vaccine should be assessed according to manufacturer guidance (and in consultation with the local immunization program) before administration. Vaccine wastage due to cold-chain failures is a significant but preventable problem in global immunization programs.
What Does Priorix Tetra Contain?
Understanding what a vaccine contains is important for patients, parents, and healthcare providers, particularly when considering allergies or sensitivities. Priorix Tetra consists of two components: a lyophilized (freeze-dried) powder containing the active viral components and stabilizers, and a separate solvent to reconstitute the powder before injection.
Active Substances
Each 0.5 mL dose of reconstituted Priorix Tetra contains not less than the following quantities of live attenuated viruses:
| Virus | Strain | Minimum Titer | Production Substrate |
|---|---|---|---|
| Measles virus | Schwarz | ≥ 103.0 CCID50 | Chick embryo fibroblast cell culture |
| Mumps virus | RIT 4385 (derived from Jeryl Lynn) | ≥ 104.4 CCID50 | Chick embryo fibroblast cell culture |
| Rubella virus | Wistar RA 27/3 | ≥ 103.0 CCID50 | Human diploid (MRC-5) cells |
| Varicella-zoster virus | Oka | ≥ 103.3 PFU | Human diploid (MRC-5) cells |
CCID50 stands for cell culture infectious dose 50%, the amount of virus that infects 50% of inoculated cell cultures. PFU stands for plaque-forming units, a similar unit of viral activity. These are standard potency measurements for live viral vaccines.
Excipients (Inactive Ingredients)
In addition to the active viral components, Priorix Tetra contains the following excipients that act as stabilizers, buffers, and bulking agents to protect the viral components during freeze-drying, storage, and reconstitution:
| Ingredient | Role | Notes |
|---|---|---|
| Amino acids | Stabilizer | Protect protein structures during lyophilization |
| Lactose (anhydrous) | Bulking agent / stabilizer | Negligible quantity, not clinically relevant for lactose intolerance |
| Mannitol | Stabilizer / bulking agent | Sugar alcohol used in many pharmaceutical products |
| Sorbitol | Stabilizer | Relevant for individuals with hereditary fructose intolerance |
| Sucrose | Stabilizer | Protects viral envelope during drying |
| Medium 199 | Culture medium residue | Contains trace amounts of components from cell culture |
| Neomycin sulfate | Residual antibiotic from manufacturing | Trace amounts only; relevant only for individuals with severe neomycin allergy |
| Water for injections | Solvent (supplied separately) | Provided in a pre-filled syringe for reconstitution |
Priorix Tetra does not contain preservatives such as thiomersal (mercury-based preservatives), and it does not contain gelatin. It contains no gluten in clinically relevant amounts. For individuals with specific allergies or metabolic conditions, the ingredient list should be reviewed carefully in consultation with a healthcare provider.
Appearance and Pack Sizes
Before reconstitution, the powder is a white to slightly pink pellet. The solvent is a clear and colorless liquid. After reconstitution, the vaccine appears as a clear, colorless to slightly yellow solution. Priorix Tetra is supplied in single-dose packaging: a vial containing the lyophilized powder plus a pre-filled syringe of solvent, with one or two separate needles depending on the presentation. Pack sizes of 1, 10, or 20 may be available depending on the country and distribution channel.
Marketing Authorization Holder and Manufacturer
Priorix Tetra is manufactured and marketed by GlaxoSmithKline (GSK) Biologicals S.A., based in Rixensart, Belgium. The vaccine is authorized in numerous countries around the world. Specific authorization conditions, licensed age ranges, and availability may vary by country. Full Summary of Product Characteristics (SmPC) and national-specific labeling are available from the relevant regulatory authorities such as the European Medicines Agency (EMA), national medicines agencies, and the manufacturer.
Frequently Asked Questions About Priorix Tetra
Priorix Tetra is a combined live attenuated vaccine that provides protection in a single injection against four vaccine-preventable diseases: measles, mumps, rubella (German measles), and varicella (chickenpox). It is authorized for use in children from 11 months to 12 years of age and is typically administered as part of national routine childhood immunization programs. The vaccine offers the practical benefit of combining four immunizations into one, reducing the total number of injections a child receives.
Priorix Tetra is licensed for children from 11 months through 12 years of age. National immunization schedules typically recommend the first dose between 11 and 15 months of age and a second dose before school entry (often between 3 and 6 years old). In specific situations such as disease outbreaks or international travel to areas with ongoing transmission, an early dose may be given from 9 months of age, but this does not replace the routine two-dose series that should still be completed at the recommended ages. Your child's specific schedule depends on the national immunization program in your country, and your healthcare provider can provide exact timing.
Priorix Tetra is highly effective. Clinical trials have shown seroconversion rates of approximately 98% for measles, 96% for mumps, 99% for rubella, and 97% for varicella after a single dose in children aged 11 months and older. After two doses, protection is even more robust and long-lasting, with two-dose schedules providing approximately 98% protection against any form of varicella and over 99% protection against severe varicella. The vast majority of children who receive both doses of Priorix Tetra develop long-term, often lifelong, protection against all four diseases.
Priorix Tetra contains weakened (attenuated) forms of the four viruses, which have been modified so that they cannot cause the full clinical disease in healthy individuals. Some children develop mild, transient vaccine reactions such as low-grade fever or a faint rash 5–12 days after vaccination, which reflects the expected immune response to the attenuated viruses. These vaccine reactions are distinguishable from the wild-type diseases: they are milder, shorter in duration, and lack the serious complications of natural infection. Children with severe immunodeficiency should not receive Priorix Tetra because the attenuated viruses could replicate without adequate immune control.
Yes, according to guidance from WHO, EMA, CDC, and other international authorities, children with egg allergy — including severe allergy — can generally receive MMR and MMRV vaccines safely in routine clinical settings. Although the measles and mumps components of Priorix Tetra are produced in chick embryo cell cultures, the residual egg protein content is extremely low and not associated with allergic reactions in most children. Serious allergic reactions to MMRV vaccines are rare and more often attributed to other vaccine components such as gelatin (not present in Priorix Tetra) or neomycin. Children with documented severe allergic reactions to a previous dose should be evaluated by an allergist.
Yes, Priorix Tetra can be safely co-administered at the same visit with most other routine childhood vaccines, including diphtheria-tetanus-pertussis-containing vaccines, Haemophilus influenzae type b, hepatitis B, inactivated poliovirus, pneumococcal conjugate vaccines, meningococcal conjugate vaccines, hepatitis A, and inactivated influenza vaccine. Different injection sites should be used for each vaccine. For other live vaccines not given on the same day as Priorix Tetra, a 4-week interval is generally recommended to avoid potential reduction in immune response. Your healthcare provider will advise on the appropriate schedule.
Priorix Tetra combines measles, mumps, rubella, and varicella vaccines into a single injection, while separate administration involves one MMR injection and a second varicella injection, typically given at the same visit but in different injection sites. Both approaches provide excellent protection against all four diseases. The main difference is that combined MMRV vaccines are associated with a small additional risk of febrile seizures 5–12 days after the first dose compared to separate MMR and varicella vaccines. Because of this, some national guidelines recommend separate vaccines for the first dose and combined MMRV for the second dose. After the first dose, the febrile seizure risk with MMRV is similar to separate vaccines.
Mild fever (up to about 39 °C) and a faint rash occurring 5–12 days after Priorix Tetra are common and expected reactions. Ensure your child rests, stays well hydrated, and dresses comfortably. Paracetamol (acetaminophen) can be used at weight-appropriate doses to reduce discomfort or high fever. These symptoms typically resolve within 1–2 days. Contact your healthcare provider if your child has: fever above 39.5 °C that does not respond to antipyretics, a seizure, severe lethargy or reduced responsiveness, difficulty breathing, swelling of the face or throat, a widespread severe rash, or unusual bruising or bleeding. In a medical emergency, seek urgent medical attention immediately.
References
- European Medicines Agency (EMA). Priorix Tetra – Summary of Product Characteristics and EPAR. Latest revision 2025. Available at: European Medicines Agency.
- World Health Organization (WHO). Measles vaccines: WHO position paper – April 2017 (reaffirmed 2023/2024). Weekly Epidemiological Record. 2017;92(17):205–227.
- World Health Organization (WHO). Varicella and herpes zoster vaccines: WHO position paper, June 2014 (reaffirmed 2023). Weekly Epidemiological Record. 2014;89(25):265–287.
- Centers for Disease Control and Prevention (CDC). Use of Combination Measles, Mumps, Rubella, and Varicella Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2024;73(RR-01):1–24.
- European Centre for Disease Prevention and Control (ECDC). Measles and rubella monitoring. Stockholm: ECDC; 2025. Available at: ECDC Measles Monitoring.
- Di Pietrantonj C, Rivetti A, Marchione P, Debalini MG, Demicheli V. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database Syst Rev. 2021;11(11):CD004407. doi:10.1002/14651858.CD004407.pub5.
- Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010;126(1):e1–e8. doi:10.1542/peds.2010-0665.
- Ma SJ, Xiong YQ, Jiang LN, Chen Q. Risk of febrile seizure after measles-mumps-rubella-varicella vaccine: A systematic review and meta-analysis. Vaccine. 2015;33(31):3636–3649. doi:10.1016/j.vaccine.2015.06.009.
- Knuf M, Zepp F, Helm K, et al. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Eur J Pediatr. 2012;171(3):463–470.
- GlaxoSmithKline Biologicals. Priorix Tetra: Technical Product Information. Rixensart, Belgium; 2024.
- British National Formulary for Children (BNFC). Measles, mumps, rubella and varicella vaccine. National Institute for Health and Care Excellence (NICE). 2025.
- Strebel PM, Papania MJ, Fiebelkorn AP, Halsey NA. Measles vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin's Vaccines. 7th ed. Philadelphia: Elsevier; 2018. p. 579–618.
About Our Medical Team
All content on iMedic is created and reviewed by qualified medical professionals following international evidence-based guidelines. Our editorial process ensures accuracy, currency, and clinical relevance.
Medical Content Team
Specialists in pediatric infectious diseases, vaccinology, and clinical pharmacology with extensive experience in childhood immunization programs and MMRV vaccines.
Medical Review Board
Independent panel of board-certified physicians who verify all medical claims against current evidence and international guidelines (WHO, EMA, FDA, CDC ACIP, ECDC).
Editorial Standards
All content follows the GRADE evidence framework and is based on Level 1A evidence from systematic reviews and randomized controlled trials where available.
Independence
iMedic receives no pharmaceutical company funding or sponsorship. All content is editorially independent, ensuring unbiased medical information for patients, parents, and caregivers.